References
- Phoompoung P, Villalobos APC, Jain S, et al. Risk factors of invasive fungal infections in lung transplant recipients: a systematic review and meta-analysis. J Heart Lung Transplant. 2022;41(2):255–262.
- Gao Y, Soubani A. Advances in the diagnosis and management of pulmonary aspergillosis. Adv Respir Med. 2019;87(6):231–243.
- Qiao W, Zou J, Ping F, et al. Fungal infection in lung transplant recipients in perioperative period from one lung transplant center. J Thorac Dis. 2019;11(4):1554–1561.
- Patterson TF, Thompson GR, 3rd, Denning DW, et al. Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the infectious diseases society of america. Clin Infect Dis. 2016;63(4):e1–e60.
- Shafiei M, Peyton L, Hashemzadeh M, et al. History of the development of antifungal azoles: a review on structures, SAR, and mechanism of action. Bioorg Chem. 2020;104:104240.
- Groll AH, Gea-Banacloche JC, Glasmacher A, et al. Clinical pharmacology of antifungal compounds. Infect Dis Clin North Am. 2003;17(1):159–191, ix.
- Shi C, Xiao Y, Mao Y, et al. Voriconazole: a review of population pharmacokinetic analyses. Clin Pharmacokinet. 2019;58(6):687–703.
- Theuretzbacher U, Ihle F, Derendorf H. Pharmacokinetic/pharmacodynamic profile of voriconazole. Clin Pharmacokinet. 2006;45(7):649–663.
- Pasqualotto AC, Xavier MO, Andreolla HF, et al. Voriconazole therapeutic drug monitoring: focus on safety. Expert Opin Drug Saf. 2010;9(1):125–137.
- Han K, Capitano B, Bies R, et al. Bioavailability and population pharmacokinetics of voriconazole in lung transplant recipients. Antimicrob Agent Chemother. 2010;54(10):4424–4431.
- Klatt ME, Eschenauer GA. Review of pharmacologic considerations in the use of azole antifungals in lung transplant recipients. JoF. 2021;7(2):76.
- Andes D. Optimizing antifungal choice and administration. Curr Med Res Opin. 2013;29(Suppl 4):13–18.
- Sima M, Pokorna P, Hronova K, et al. Effect of co-medication on the pharmacokinetic parameters of phenobarbital in asphyxiated newborns. Physiol Res. 2015;64(Suppl 4):S513–S519.
- Stelzer D, Weber A, Ihle F, et al. Comparing azole plasma trough levels in lung transplant recipients: percentage of therapeutic levels and intrapatient variability. Ther Drug Monit. 2017;39(2):93–101.
- Mangoni AA, Jackson SH. Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications. Br J Clin Pharmacol. 2004;57(1):6–14.
- De Sutter PJ, Gasthuys E, van Braeckel E, et al. Pharmacokinetics in patients with cystic fibrosis: a systematic review of data published Between 1999 and 2019. Clin Pharmacokinet. 2020;59(12):1551–1573.
- Dvořáčková E, Šíma M, Petrus J, et al. Ganciclovir pharmacokinetics and individualized dosing based on covariate in lung transplant recipients. Pharmaceutics. 2022;14(2):408.